Resources Management Corp CT ADV Cuts Stock Holdings in Danaher Corporation $DHR

Posted by Shane Hupp on Jun 15th, 2026

Resources Management Corp CT ADV lowered its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 44.4% during the fourth quarter, Holdings Channel reports. The fund owned 34,430 shares of the conglomerate’s stock after selling 27,524 shares during the period. Danaher comprises 1.0% of Resources Management Corp CT ADV’s investment portfolio, making the stock its 22nd largest position. Resources Management Corp CT ADV’s holdings in Danaher were worth $7,882,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of DHR. JPL Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth $25,000. Elevated Capital Advisors LLC purchased a new stake in shares of Danaher during the fourth quarter worth $26,000. WFA of San Diego LLC purchased a new stake in shares of Danaher during the second quarter worth $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Danaher during the third quarter worth $27,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Danaher during the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $179.95 on Monday. The stock’s 50-day moving average is $180.93 and its two-hundred day moving average is $204.62. The firm has a market cap of $127.37 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 2.30 and a beta of 0.81. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.88 earnings per share. Analysts predict that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Morgan Stanley cut their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Rothschild & Co Redburn set a $205.00 price objective on Danaher in a research report on Friday, April 17th. Finally, Royal Bank Of Canada initiated coverage on Danaher in a report on Thursday, May 14th. They issued an “outperform” rating and a $200.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $233.61.

Check Out Our Latest Stock Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.